Until the development of ampicillin resistance among Shigella in recent years, ampicilhin has been the highly effective treatment of choice in acute shigellosis. For ampicillin-susceptible Shigella infections, ampicillin therapy significantly reduced the duration and severity of the illness, and fecal shedding of Shigella in children and adults, when compared with either oral kanamycin or placebo (3, 14) . However, in recent years, many Shigella flexneri and Shigella sonnei, the two most common strains that cause shigellosis in the United States, have become resistant to ampicillin (9, 10) . Sulfamethoxazoletrimethoprim (SXT) is effective in vitro against ampicillin-resistant strains of Shigella (4) . SXT has been found to be effective in treating children with acute shigellosis (2, 6, (11) .
Clinical data. Each day a physician who did not know the antibiotic administered recorded the foilowing data for the previous 24 h: maximum temperature, number of loose bowel movements (with or without gross blood), nausea, vomiting, anorexia, abdominal pain, headache, myalgias, and malaise.
Clinical improvement was defined as greater than 50% reduction in symptom count, with each of the above symptoms represented by 1. Statistical analyses were done using Student's t test.
RESULTS
As shown in Table 1 , 27 patients met the criteria for admission to the study; 14 were randomly assigned to receive ampicillin, and 13 were assigned to receive SXT. The ages, sex distribution, and duration of illness were comparable in the treatment subgroups. Responses in terms of reduction in fever and number of loose stools over the 5 days of daily follow-up are shown in Fig. 1 . Fever and diarrhea in the SXT group were significantly reduced within 24 h (P < 0.001 for both symptoms). Significant reductions in fever and diarrhea in the ampicillin-treated group occurred 1 day later, within 48 h.
Of the 27 patients, 19 had culture-proven shigellosis. Seventeen had Shigella flexneri, and two had Shigella sonnei. Of these 19 patients, 6 had ampicilhin-resistant Shigella. All Shigella, isolates were susceptible to SXT (minimum inhibitory concentrations less than 20 and 1 ug of sulfamethoxazole and trimethoprim per ml, respectively). The responses of fever and diarrhea in these treatment subgroups are shown in Fig.  2 . Responses of the eight patients with documented shigellosis given SXT were comparable to those of the eight patients with ampicillinsusceptible Shigella who were treated with ampicillin. However, the three patients with ampicillin-resistant Shigella who were treated with ampicillin appeared to respond more slowly.
Two patients were quite ill at the end of 48 to 72 h, necessitating breaking of the blind treatment code. Both patients were receiving ampicillin, and both were changed to SXT; they subsequently improved. One of these two had a subsequently documented ampicillin-resistant organism. Two other patients with ampicillinresistant organisms treated with ampicillin recovered uneventfully within 3 days. The three patients with ampicillin-resistant organisms treated with SXT showed ificant clinical improvement within 24 h and had completely recovered by day 2 of therapy.
The results of the stool cultures are shown in Fig. 3 . Although the numbers were small, there was again a tendency toward prolonged culture positivity in the ampicillin-resistant shigellosis treated with ampicillin. In contrast, none of the 25 cultures obtained after the first day from the 16 patients treated with SXT or ampicillin (who had ampicillin-sensitive isolates) were culture positive. The two patients who had positive stool cultures for Shigella after 48 h had both received ampicillin. One was the patient mentioned above who had an ampicillin-resistant organism and who failed on ampicillin therapy. The other patient had an ampicillin-susceptible organism and recovered uneventfully.
DISCUSSION
Shigellosis is a major problem in areas throughout the world where sanitation is poor, including the United States. Resistance to ampicillin and sulfonamides, the only two antibiotics of proven efficacy in adults, in recent years has become quite common. The fact that 6 (32%) of our 19 isolates were ampicillin resistant reflects its widespread occurrence among Shigella (4, 9, 10). Among the few potentially effective antimicrobial agents to which these Shigella remain susceptible in vitro at this time is SXT. Over a 2-year period at the Fort Defiance Indian Hospital, we treated 27 adults who required dividuals had a family member with a simultaneous similar illness that was documented shigellosis by culture. Examination for fecal leukocytes in patients suspected of having shigellosis facilitates initiation of antimicrobial therapy early in the course of the illness and thereby prompt reduction in symptoms and excretion of the pathogen. Lacking evidence of shigellosis, other potentially invasive pathogens should be considered which might require different or no antimicrobial therapy, such as Campylobacter fetus subsp. jejuni or Sablonella infections, respectively. C. fetus subsp. jejuni infections are being increasingly recognized throughout the world, including the United States, and should be sought using specially selective media (1) .
SXT is as effective as ampicillin in the treatment of moderately severe ampicillin-susceptible Shigella infections in adults, and appears to be effective in treating patients with ampicillinresistant shigellosis. Therefore, SXT appears to be the drug of choice for symptomatic shigellosis in areas where ampicillin resistance is common.
